|
⚲
|
| Keyboard |
| Elmind Capital LP
✚
|
|
|---|---|
| CRD # | 333910 |
| SEC # | 801-131599 |
| CIK # | 0002052213 |
| AUM | 613.6 M (2026-03-27) |
| Employees | 2 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 650-796-6466 |
| Address | |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| UNUM Therapeutics Inc | 45.1 | ||
| Syndax Pharmaceuticals Inc | 43.3 | ||
| Celldex Therapeutics Inc | 27.4 | ||
| CytomX Therapeutics Inc | 21.4 | ||
| CG Oncology Inc | 19.7 | ||
| Vera Therapeutics Inc | 19.4 | ||
| Vaxcyte Inc | 18.4 | ||
| Pharvaris NV | 13.4 | ||
| TYRA Biosciences Inc | 13.4 | ||
| Beam Therapeutics Inc | 11.4 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Elmind Capital Master Fund LP | [2025-03-31] | 218.6 M | 613.6 M |
| Filed 2025-12-16 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 3 | 613.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 3 | 613.6 |
| By Discretionary | ||
| Discretionary | 3 | 613.6 |
| Non-Discretionary | 0 | 0.0 |
| Total | 3 | 613.6 |
| By Non-United States Persons | ||
| Non-United States Persons | 351.6 | |
| United States Persons | 262.0 | |
| Total | 3 | 613.6 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Ronan Guilfoyle | Director | 358 | 108 | |
| Brad Cowdroy | Director | 58 | 16 | |
| Ernest Verrico | Executive Officer | 4 | 2 | |
| Lihan Sun | Executive Officer | 2 | 2 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0002052213] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Comparable Firms | State | AUM |
|---|---|---|
|
Neumann Advisory Hong Kong Limited
✚
|
622.9 M | |
|
Shoten Capital LP
✚
|
TX | 622.4 M |
|
Sancus Capital Management LP
✚
|
CA | 618.9 M |
|
Rivermont Capital Management LP
✚
|
NY | 617.9 M |
|
Kettle Hill Capital Management LLC
✚
|
NY | 615.5 M |
|
Turas Capital Management LP
✚
|
MA | 613.5 M |
|
Catalur Capital Management LP
✚
|
NY | 611.9 M |
|
Soapstone Management LP
✚
|
MD | 610.1 M |
|
Kah Capital Management LLC
✚
|
VA | 605.3 M |
|
Eagle Health Investments LP
✚
|
CT | 605.3 M |